查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1737105

全球重度憂鬱症(MDD) 市場規模（按產品、應用和地區分類）- 預測

Global Major Depressive Disorder (MDD) Market Size By Product, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

重度憂鬱症（MDD）市場規模及預測

預計 2024 年全球重度憂鬱症(MDD) 市場規模將達到 57 億美元，到 2032 年將達到 106 億美元，預測期內（2026-2032 年）的複合年成長率為 8.4%。

推動全球重度憂鬱症（MDD）市場發展的因素

重度憂鬱症(MDD) 市場促進因素可能受到多種因素的影響。這些因素包括：

重度憂鬱症（MDD）的盛行率和發生率決定了醫療保健和處方藥的需求。由於MDD是一種全球流行的精神疾病，其盛行率直接影響市場規模。

研發：研發促進新藥、治療方法和新治療方式的開發，有助於擴大市場。資助MDD治療研發的製藥公司有助於擴大市場。

法規環境：監理、核准和政策變化影響市場動態。監管機構對新藥和新適應症的核准會對市場擴張產生重大影響。

技術進步：經顱磁刺激 (TMS) 和氯胺酮輸注療法等治療方式以及腦部影像技術等診斷程序的創新將透過開闢管理 MDD 的新途徑來影響市場。

意識和教育工作：透過宣傳和教育宣傳活動提高大眾對重度憂鬱症（MDD）等心理健康問題的認知，可以鼓勵早期診斷和尋求治療的行為，進而影響市場。

醫療保健提供者的可及性、報銷指南以及MDD治療的保險覆蓋範圍都會影響市場成長。優惠的報銷政策和完善的醫療基礎設施可以提升市場潛力。

人口趨勢：MDD 的流行以及治療需求可能會受到人口老化和生活方式改變等因素的影響。

合併症：慢性病和焦慮症是一種經常與重度憂鬱症（MDD）同時發生的疾病。某些合併症的盛行率將影響治療前景和市場動態。

經濟因素：保險覆蓋範圍、醫療費用支出和收入水準等許多經濟因素都會影響 MDD 治療的可近性和可負擔性，進而影響市場成長。

患者偏好和治療結果：市場趨勢由患者對心理治療和藥物治療等特定治療方式的偏好以及治療在實現預期結果方面的有效性所驅動。

限制全球重度憂鬱症（MDD）市場的因素

有幾個因素可能會對重度憂鬱症(MDD) 市場造成限制和挑戰。這些因素包括：

恥辱和意識：儘管人們努力提高認知，重度憂鬱症（MDD）等精神疾病仍然帶有恥辱感，這可能會阻止人們接受治療並限制市場擴張。

監管障礙：針對新藥和新療法的嚴格指導方針和核准程序可能會阻礙治療 MDD 的新藥的發現和推出，從而減緩市場擴張。

昂貴的藥物和心理治療：MDD 的治療通常需要藥物和心理治療相結合，這些治療費用昂貴且並非人人都能接受，這可能會阻礙市場擴張，尤其是在醫療保健和保險覆蓋有限的地區。

非專利競爭：學名藥抗憂鬱症的推出或專利到期可能會導致品牌藥價格下降、銷售減少，進而影響市場規模。

現有治療方法療效有限：儘管治療重度憂鬱症（MDD）的方法多種多樣，但並非所有方法都對每個人都有效。隨著相關人員和患者不斷尋求更有效的治療方法，這些限制可能會阻礙市場擴張。

共病性與複雜性：重度憂鬱症的治療往往因其他精神和軀體疾病的共病而變得複雜。開發有效的共病治療方法極具挑戰性，這可能會阻礙市場擴張。

研發相關風險：臨床試驗失敗和發現非預期副作用是精神健康領域研發的兩大固有風險。這些風險可能抑制新型MDD療法的資金投入，並阻礙市場擴張。

獲得醫療保健服務：獲得精神健康服務的不平等，特別是在貧困地區和農村地區，可能會限制 MDD治療方法的接受度並抑制其發展。

治療抗性：患有抗治療性憂鬱症的重重度憂鬱症憂鬱症患者可能對傳統療法無反應。針對該族群的開發新藥面臨障礙，可能限制市場擴張。

目錄

第 1 章全球重度憂鬱症(MDD) 市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

4. 全球重度憂鬱症（MDD）市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球重度憂鬱症（MDD）市場（按產品）

  • 概述
  • 苯二氮平類藥物
  • 抗憂鬱症
  • SSRI
  • SNRI
  • 其他

第6章 全球重度憂鬱症（MDD）市場（按應用）

  • 概述
  • 診所
  • 醫院
  • 其他

第7章全球重度憂鬱症（MDD）市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

8. 全球重度憂鬱症（MDD）市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • Bristol-Myers Squibb
  • Pfizer
  • H. Lundbeck
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Merck
  • Forest Laboratories
  • AstraZeneca
  • Johnson & Johnson
  • Eli Lily

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 50843

Major Depressive Disorder (MDD) Market Size And Forecast

Major Depressive Disorder (MDD) Market size was valued at USD 5.7 Billion in 2024 and is projected to reach USD 10.6 Billion by 2032, growing at a CAGR of 8.4 % during the forecast period 2026-2032.

Major Depressive Disorder (MDD) Market is estimated to grow at a CAGR of 8.4% & reach US$ 10.6 Bn by the end of 2032

Global Major Depressive Disorder (MDD) Market Drivers

The market drivers for the Major Depressive Disorder (MDD) Market can be influenced by various factors. These may include:

MDD's prevalence and incidence rates are what determine how much demand there is for medical care and prescription drugs. Given that MDD is a prevalent mental health disorder globally, the market size is directly impacted by its prevalence.

Research and Development: New medicines, therapies, and treatment modalities are developed as a result of research advancements, which propel market expansion. Pharmaceutical firms that fund MDD therapy R&D help to expand the market.

Regulatory Environment: Modifications to regulations' rules, clearances, and policies have an impact on the dynamics of the market. The approval of new medications or indications by regulators can have a big impact on market expansion.

Technological Advancements: By opening up new paths for MDD management, technological innovations in therapeutic modalities like transcranial magnetic stimulation (TMS) and ketamine infusion therapy, as well as diagnostic procedures like brain imaging technologies, have an impact on the market.

Initiatives for Awareness and Education: Raising public knowledge of mental health issues, such as Major Depressive Disorder (MDD), via advocacy and educational campaigns, can encourage early diagnosis and treatment-seeking behaviour, which in turn can influence the market.

Access to healthcare providers, reimbursement guidelines, and insurance coverage for MDD therapies all have an impact on market expansion. Expanding market potential can be achieved through favourable reimbursement policies and improvements in the healthcare infrastructure.

Demographic Trends: The prevalence of MDD and, consequently, the need for therapies can be influenced by factors such as ageing populations and shifting lifestyles.

Comorbid ailments: Chronic illnesses and anxiety disorders are two examples of medical ailments that frequently coexist with MDD. The treatment landscape and market dynamics are influenced by the prevalence of certain comorbidities.

Economic Factors: A number of economic factors, including insurance coverage, healthcare spending, and income levels, have an impact on the accessibility and affordability of MDD therapies, which in turn has an impact on market growth.

Patient Preferences and Treatment Outcomes: What drives market trends are patient preferences for particular treatment modalities, such psychotherapy or medication, as well as how well treatments work to achieve desired results.

Global Major Depressive Disorder (MDD) Market Restraints

Several factors can act as restraints or challenges for the Major Depressive Disorder (MDD) Market. These may include:

Stigma and Awareness: Despite initiatives to increase awareness, there is still stigma associated with mental health conditions like Major Depressive Disorder (MDD). This might prevent people from getting treatment, which in turn restricts the expansion of the market.

Regulatory Obstacles: Tight guidelines and rigorous approval procedures for novel medications and treatments can hinder the creation and launch of MDD remedies, which will slow the market's expansion.

Expensive Medication and Therapy: MDD treatment frequently entails a mix of medication and therapy, which can be costly and may not be accessible to all individuals. This may prevent the market from growing, particularly in areas with poor access to or coverage of healthcare.

Generic Competition: The introduction of generic copies of antidepressant treatments and the expiration of patents on those products may result in price erosion and lower sales for branded drugs, which may have an effect on the size of the market as a whole.

Limited Effectiveness of Current Treatments: Although there are a number of MDD treatment choices available, not all individuals will benefit from them, which can cause frustration and necessitate the use of alternative therapies. This restriction may impede market expansion as healthcare practitioners and patients look for more effective therapies.

Comorbidities and Complexity: Treatment for MDD is frequently complicated by the coexistence of other mental health illnesses or physical ailments. It can be difficult to develop treatments that successfully treat certain comorbidities, which could impede market expansion.

Risks associated with R&D: Clinical trial failure and the identification of unanticipated adverse effects are two of the inherent risks associated with research and development in the field of mental health. These dangers may discourage funding for novel MDD treatments, which would hinder market expansion.

Access to Healthcare Services: Inequalities in mental health service accessibility, particularly in underprivileged or rural regions, may restrict the acceptance of MDD therapies and impede their growth.

Resistance to Treatment: Traditional therapy may not work for certain patients with Major Depressive Disorder (MDD) if they are experiencing treatment-resistant depression. There are obstacles in developing new medicines for this demographic, which could limit market expansion.

Global Major Depressive Disorder (MDD) Market Segmentation Analysis

The Global Major Depressive Disorder (MDD) Market is Segmented on the basis of Product, Application, And Geography. Major Depressive Disorder (MDD) Market Segmentation Analysis

Major Depressive Disorder (MDD) Market, By Product

  • Benzodiazepines
  • Antidepressant Drugs
  • SSRIs
  • SNRIs
  • Others

Based on Product, the market is bifurcated into Benzodiazepines, Antidepressant Drugs, SSRIs, SNRIs, and Others. The Antidepressant Drugs segment holds the largest market share during the forecast period. In adults, MDD is common in those who are 25-44 years. Within a complete lifetime, major depression touches 10% - 25% of women and 5% - 12% of men. Thus, increasing population count prone to these diseases is driving the demand for this segment.

Major Depressive Disorder (MDD) Market, By Application

  • Clinics
  • Hospitals
  • Others

Based on Application, the market is bifurcated into Clinics, Hospitals, and Others. The Clinics segment retains the largest market share and is predicted to witness the highest CAGR during the forecast period. People are affected in various ways by major depression. Some people have to feel agitated and irritable, trouble sleeping, and have sudden weight loss. These factors are fueling the demand for this segment during the forecast period.

Major Depressive Disorder (MDD) Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Major Depressive Disorder (MDD) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America holds the largest market share. The expanded awareness about multiple depression conditions in the region. The U.S. represents the biggest market for major depressive disorder (MDD) in North America, accompanied by Canada. In Europe, Germany, France, Italy, and Spain account for a major share of the Major Depressive Disorder (MDD) Market. This market in Asia is anticipated to expand at a notable rate over the forecast years.

Key Players

  • The major players in the Major Depressive Disorder (MDD) Market are:
  • Bristol-Myers Squibb
  • Pfizer
  • H. Lundbeck
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Merck
  • Forest Laboratories
  • AstraZeneca
  • Johnson & Johnson
  • Eli Lily.IBM Corporation
  • Cleo Communications, Inc.
  • Signiant, Inc.
  • Broadcom, Inc.
  • Wipro Limited

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Benzodiazepines
  • 5.3 Antidepressant Drugs
  • 5.4 SSRIs
  • 5.5 SNRIs
  • 5.6 Others

6 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Clinics
  • 6.3 Hospitals
  • 6.4 Others

7 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Bristol-Myers Squibb
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Pfizer
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 H. Lundbeck
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 GlaxoSmithKline
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Sanofi-Aventis
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Merck
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Forest Laboratories
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 AstraZeneca
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Johnson & Johnson
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Eli Lily
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research